Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy
NCT ID: NCT00896831
Last Updated: 2009-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
96 participants
INTERVENTIONAL
2008-11-30
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-ornithine L-aspartate in Overt Hepatic Encephalopathy
NCT01722578
Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy
NCT00433368
Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.
NCT01041755
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure
NCT00470314
Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy
NCT05920213
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
L-ornithine-L-aspartate
5 g L-ornithine-L-aspartate (1 sachet) three times per day for 60 days
L-ornithine-L-aspartate
L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
placebo
5 g (1 sachet) of placebo comparator three times per day for 60 days
placebo
Placebo: 5 g (1 sachet) three times per day for 60 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-ornithine-L-aspartate
L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
placebo
Placebo: 5 g (1 sachet) three times per day for 60 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Use of drugs to treatment of hepatic encephalopathy (lactulose, neomycin)
* Psychoactive substance use within 72 hours
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital de Clinicas de Porto Alegre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hospital de Clínicas de Porto Alegre
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mário R Álvares-da-Silva, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital de Clínicas de Porto Alegre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
08461
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.